RT @DrMiniDey: Mepolizumab (anti-IL5) shown to be clinically beneficial and well-tolerated in the long-term for patients
Tweet Content
Mepolizumab (anti-IL5) shown to be clinically beneficial and well-tolerated in the long-term for patients with #EGPA, with a 50% reduction in #steroid dose in the study cohort.
Abs#1427 #ACR20 @RheumNow #Vasculitis
https://t.co/elr6VR7447
Links
Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) - An …
https://acrabstracts.org/abstract/anti-il5-therapy-for-eosinophilic-granulomato…
Show on Archive Page
On
Display in Search Results
On